U.S. Markets close in 2 hrs 14 mins

Q BioMed Inc. Announces FDA Filing for Strontium Chloride Sr89 Injection USP for Relief of Metastatic Cancer Bone Pain

Prior Approval Supplement Filing Under GDUFA Guidelines is Final Step in Approval Process


NEW YORK, Aug. 20, 2018 /PRNewswire/ -- Q BioMed Inc. (QBIO) (QBIO), a commercial stage biotechnology acceleration development company, and BioNucleonics, licensor of Strontium 89 Chloride, announce submission of a supplemental regulatory filing to the FDA for the approval of a new manufacturing facility. Once cleared by the FDA, the facility will be permitted to manufacture Strontium Chloride Sr89 Injection USP in accordance with cGMP. Strontium Chloride Sr89 Injection USP is an FDA-approved non-opioid injectable radiopharmaceutical indicated to relieve cancer bone pain in patients with painful skeletal metastases.

Oncologic bone pain palliation is an area of increasing unmet need. Advances in cancer treatments and earlier diagnosis have extended survival in patients with breast and prostate cancers, with patients living an average of 2 to 3 years after a diagnosis of bone metastasis. It has been estimated that 65% to 75% of patients with breast or prostate cancer will develop bone metastases; and lung, along with bladder and thyroid cancer frequently metastasize to bone. Data suggest that approximately 75% of patients with bone metastases complain of pain as their main symptom and as the dominant reason for a decreased quality of life.


Sr-89 is an effective, safe, non-narcotic analgesic alternative for the treatment of patients with painful skeletal metastases. Numerous studies have demonstrated significant palliative benefit in the management of painful bone metastases.  Treatment with Sr89 has led to a significant improvement in quality of life for patients with metastatic bone disease associated with breast, lung and prostate cancer and has been demonstrated to reduce or eliminate the need for opioids.


Sr89 works by delivering radiation local to the bone metastases that results in pain relief by selectively targeting and accumulating in metastatic bone lesions with minimal risk of toxicity to surrounding normal tissue. Unlike many other therapies that demand that patients make repeated visits to hospitals for a course of treatment, Strontium Chloride Sr89 Injection is administered in a single visit and offers pain relief that can last for 3 months or more. Decades of use have shown it to be safe and tolerable. Sr89 is covered under most insurance plans, including Medicare.

QBioMed CEO, Denis Corin said, "This comprehensive filing required by the FDA is the final step in what has been a long process. Our U.S. based contract manufacturing facility is uniquely equipped for the complex manufacturing of this product, and we will be ready to make the product available on approval. We will be the only commercial manufacturer of this drug in the U.S. and look forward to serving and growing the market for years to come. We believe this proven therapy has been vastly underutilized and can substantially improve the quality of the lives of those afflicted by this very painful cancer metastases. We believe there are approximately 280,000 people currently living with metastatic bone disease in the US alone, in addition to many thousands of cancer patients who will develop skeletal metastases every year as a result of their disease progression. This represents a significant market for us and an opportunity to improve the lives of many people and their families and caregivers."

Please visit www.strontium89.com for more information.

About Q BioMed Inc.

Q BioMed, Inc. is a biomedical acceleration and development company. We are focused on licensing and acquiring biomedical assets across the healthcare spectrum. Q BioMed is dedicated to providing these target assets the strategic resources, developmental support and expansion capital they need to meet their developmental potential so that they can provide products to patients in need.

Please visit www.qbiomed.com and sign up to receive regular updates. Follow us on social media @QBioMed.

About Strontium Chloride Sr89 Injection USP

INDICATIONS AND USAGE:  Strontium Chloride Sr-89 Injection USP, is indicated for the relief of bone pain in patients with painful skeletal metastases. The presence of bone metastases should be confirmed prior to therapy.

CONTRAINDICATIONS:  None known.

WARNINGS: Use of Strontium Chloride Sr89 Injection USP in patients with evidence of seriously compromised bone marrow from previous therapy or disease infiltration is not recommended unless the potential benefit of the treatment outweighs its risks. Bone marrow toxicity is to be expected following the administration of Strontium Chloride Sr89 Injection USP, particularly white blood cells and platelets. The extent of toxicity is variable. It is recommended that the patient's peripheral blood cell counts be monitored at least once every other week. Typically, platelets will be depressed by about 30% compared to pre-administration levels. The nadir of platelet depression in most patients is found between 12 and 16 weeks following administration of Strontium Chloride Sr89 Injection USP. White blood cells are usually depressed to a varying extent compared to pre-administration levels. Thereafter, recovery occurs slowly, typically reaching pre-administration levels six months after treatment unless the patient's disease or additional therapy intervenes. In considering repeat administration of Strontium Chloride Sr89 Injection USP, the patient's hematologic response to the initial dose, current platelet level and other evidence of marrow depletion should be carefully evaluated. Verification of dose and patient identification is necessary prior to administration because Strontium Chloride Sr89 Injection USP delivers a relatively high dose of radioactivity.

Forward-Looking Statements

This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements include, but are not limited to, any statements relating to our growth strategy and product development programs and any other statements that are not historical facts. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: inspection of the proposed third-party manufacturing facility by the FDA or other comments or requests from the FDA in connection with the above mentioned regulatory filing; failure of the proposed third-party manufacturing facility to pass an inspection by the FDA; regulatory risks; risks related to our growth strategy; risks relating to the results of research and development activities; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; the early stage of products under development; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.

 

Contact
Denis Corin
CEO
Q BioMed Inc.
+1-888-357-2435

 

Cision

View original content:http://www.prnewswire.com/news-releases/q-biomed-inc-announces-fda-filing-for-strontium-chloride-sr89-injection-usp-for-relief-of-metastatic-cancer-bone-pain-300699377.html

  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of BUR.L earnings conference call or presentation 13-Mar-19 2:00pm GMT

    And what this chart -- what the message of this chart is, is not only that over time we've historically deployed 84% of the commitments that we've written, and that's important as a way of making sure that we're actually going to make money on the commitments that we write. But what this chart also shows you is that dynamic that I was describing earlier about 2017. If you look at the black line, the black line tells you in 2017, what percentage of each year's commitments were deployed.

  • Business
    Barrons.com

    AMD Stock Soars After Analyst Says It Won Google Cloud-Gaming Deal

    (MS) is telling its clients that Advanced Micro Devices (ticker: AMD) technology will be used in Google's upcoming cloud-gaming offering. On Tuesday, the firm's analyst Joseph Moore expressed surprise that AMD was able to succeed with its graphics technology, which he has said is less appealing than comparable technology available elsewhere. “AMD announced that it is working with Google's 'Project Stream,” which we believe will be the basis for Google's cloud gaming initiative,” he wrote, referring to an earlier disclosure by the semiconductor company.

  • Google is launching a game-streaming service called Stadia
    Business
    Engadget

    Google is launching a game-streaming service called Stadia

    Stadia will be able to stream games in 4K, 60FPS and HDR color at launch, but eventually it'll support up to 8K. However, it's also much more than that. More connection means more consumerism, and Stadia will allow developers to sell their games in new ways, including directly via YouTube and Twitch live streams. For example, load up a trailer for Assassin's Creed: Odyssey on YouTube and, at the end, click the "Play" button and the game will load in as little as five seconds in your Chrome browser, ready to play.

  • Final trades: CVS Health, Facebook, Netflix, & a Mexico play
    Business
    CNBC Videos

    Final trades: CVS Health, Facebook, Netflix, & a Mexico play

    The "Halftime Report" traders give their top stocks to watch for the second half.

  • Business
    American City Business Journals

    Is Southwest Airlines heading to Europe next?

    With much less fanfare on Monday afternoon, Southwest Airlines flew its first flight with passengers from Hawaii back to the mainland. Southwest's entrance into Hawaii is likely to lower the cost of flying to the islands. “It's not just what Southwest does, but what do the competitors start doing, and then what is American forced to do,” explained Steve Cosgrove, owner of Dynamic Travel in Southlake.

  • These 3 Cannabis Stocks Are Set to Skyrocket, Say Analysts
    Business
    SmarterAnalyst

    These 3 Cannabis Stocks Are Set to Skyrocket, Say Analysts

    Without further ado, here are three of the best cannabis stocks to be looking at right now: Aphria Has More Room to Run Over the last three years, Aphria (APHA) shares have exploded by over 850%, and according to the Street significant further upside potential lies ahead. That's despite a horrendous 2018, which featured a hostile takeover attempt, the exit of its CEO and allegations from a short-seller that insiders profited from acquiring international businesses at highly inflated prices. This was the central accusation of a short report that roiled the stock price, and renewed concerns about the company's corporate governance.

  • 7 red flags that could trigger an IRS audit of your taxes
    Business
    USA TODAY

    7 red flags that could trigger an IRS audit of your taxes

    For instance, the IRS examined 0.5 percent of all individual returns for the 2017 tax year. The examination rate increased to 0.8 percent for non-business filers reporting $200,000 to $999,999 in income, and 4.4 percent for individual returns with $1 million or more in income. Once you cross that $1 million income threshold, your tax return is more complex,” Allec says.

  • 3 Things Investors Need to Know About Plug Power's Q4 Earnings
    Business
    Motley Fool

    3 Things Investors Need to Know About Plug Power's Q4 Earnings

    Failing to meet analysts' estimates of a $0.06 loss per share, Plug Power (NASDAQ: PLUG), a leader in fuel cells, reported a loss of $0.08 per share for Q4 2018. Citing "technical leadership and continued new product deployment" in its letter to shareholders, Plug Power generated positive adjusted EBITDA -- $500,000 -- in a quarter for the first time in the company's history. Expanding our view, we find that the company's overall performance last year reflects an improvement year over year, as Plug Power reported adjusted EBITDA of negative $17.5 million in 2018, versus negative $32.8 million in 2017.

  • Were Hedge Funds Right About Alibaba Group Holding Limited (BABA)?
    Business
    Insider Monkey

    Were Hedge Funds Right About Alibaba Group Holding Limited (BABA)?

    Hedge fund managers like Andreas Halvorsen, Chase Coleman, or Carl Icahn became billionaires through reaping large profits for their investors, which is why piggybacking their stock picks may provide us with significant returns as well. Many hedge funds, like Paul Singer's Elliott Management, are pretty secretive, but we can still get some insights by analyzing their quarterly 13F filings. One of the most fertile grounds for large abnormal returns is hedge funds' most popular small-cap picks, which are not so widely followed and often trade at a discount to their intrinsic value.

  • Business
    Barrons.com

    Capt. 'Sully' Sullenberger: Where Boeing and the FAA Went Wrong in This 'Ugly Saga'

    BA) and the FAA have been found wanting in this ugly saga that began years ago but has come home to roost with two terrible fatal crashes, with no survivors, in less than five months, on a new airplane type, the Boeing 737 Max 8, something that is unprecedented in modern aviation history. For too many years, the FAA has not been provided budgets sufficient to ensure appropriate oversight of a rapidly growing global aviation industry. Staffing has not been adequate for FAA employees to oversee much of the critically important work of validating and approving aircraft certification.

  • DowDuPont Subsidiary Confirms Share BuyBack after Separation
    Business
    Market Realist

    DowDuPont Subsidiary Confirms Share BuyBack after Separation

    DowDuPont Subsidiary Confirms Share BuyBack after SeparationDow confirms stock repurchase after separation In a press release on March 18, 2019, Dow, which is set to be separated from DowDuPont (DWDP), announced that it had confirmed the adoption of

  • Business
    Thomson Reuters StreetEvents

    Edited Transcript of LINC earnings conference call or presentation 6-Mar-19 3:00pm GMT

    Third, we continue to drive marketing initiatives, resulting in approximately $500,000 of additional spend in the fourth quarter of 2018 compared to the fourth quarter of the prior year. While marketing investments are up, the cost to obtain prospective students has remained relatively flat when compared to the prior year quarter, indicating that the marketing dollars are providing return on our investment and should continue to yield start growth during 2019. We are confident that the increased marketing investment has been a strong contributor to our continuous start growth, especially in the adult population.

  • What Instagram Shopping App Test Means For Shopify Stock, PayPal
    Business
    Investor's Business Daily

    What Instagram Shopping App Test Means For Shopify Stock, PayPal

    Instagram, the photo-sharing app of Facebook, is testing a shopping feature called Checkout, according to reports. Shopify stock fell on the news, though Instagram in a blog said the e-commerce tool provider could be a potential partner. Shopify stock slipped 2.1% to 201.47 in midday trading on the stock market today.

  • HD Supply Beats Earnings, Revenue Views But Guides Q1 Low
    Business
    Investor's Business Daily

    HD Supply Beats Earnings, Revenue Views But Guides Q1 Low

    Industrial distributor HD Supply beat Q4 earnings and revenue forecasts while giving mixed guidance for the quarter and year ahead. HD Supply Earnings Estimates: Wall Street expected HD Supply earnings to vault 37% to 67 cents, according to Zacks Investment Research. Revenue was seen swelling 18% to $1.4 billion.

  • The Only 4 Pure-Play Pot Stocks That Are Profitable on an Operating Basis
    Business
    Motley Fool

    The Only 4 Pure-Play Pot Stocks That Are Profitable on an Operating Basis

    Innovative Industrial Properties Cannabis real estate investment trust (REIT) Innovative Industrial Properties (NYSE: IIPR) debuted on the New York Stock Exchange in December 2016, and it didn't take long for the company to generate recurring profits. The marijuana REIT business model involves buying land and facilities (e.g., cultivation or processing) involved in the weed supply chain, then leasing out these facilities for an extended period of time in order to profit from the rental income. Many years down the road, these assets can be sold for a profit, and the capital received from the sale can be used to start the investment process anew.

  • Boeing CEO's Public Apology
    Business
    Yahoo Finance Video

    Boeing CEO's Public Apology

    Boeing CEO releases apology statement to airlines, passengers, and the Aviation Community. Yahoo Finance's Adam Shapiro, Julie Hyman, Ethan Wolff-Mann, and Rick Newman join The Economist Media Editor Gady Epstein to discuss.

  • 3 Dividend Stocks Ideal for Retirees
    Business
    Motley Fool

    3 Dividend Stocks Ideal for Retirees

    A small, fast-growing dividend Steve Symington (Universal Display): Universal Display first initiated a tiny $0.03-per-share dividend in early 2017, good for an annual yield of around 0.14% at the time. But I singled out the stock as a promising long-term play because management called the minuscule payout "a good place to start," indicating it had room to grow along with the organic LED (OLED) market. Fast-forward to now, and though Universal Display's share price has nearly doubled since then, the stock yields around 0.25% annually as the company has increased its quarterly payout to $0.10 per share.

  • Where Will CenturyLink Be in 5 Years?
    Business
    Motley Fool

    Where Will CenturyLink Be in 5 Years?

    A new age of internet connectivity and communication is upon us, and CenturyLink (NYSE: CTL) could find itself on the outs. Mobile network operators like Verizon (NYSE: VZ) are rolling out super-fast 5G connectivity technology, which could put them in direct competition with legacy internet service providers (ISPs) like CenturyLink, not to mention further accelerate declining phone line and cable TV business. CenturyLink may be in the woods at the moment, but not all is lost.

  • Novavax (NVAX) Q4 2018 Earnings Conference Call Transcript
    Business
    Motley Fool

    Novavax (NVAX) Q4 2018 Earnings Conference Call Transcript

    Dr. Gregory Glenn, our president of research and development, will also be available for the Q&A portion of the call. Before we begin our prepared remarks, I need to remind you that we will be making forward-looking statements during the teleconference that could include financial, clinical or commercial projections.

  • Domo Still Looks Cheap After Its Post-Earnings Rally
    Business
    Motley Fool

    Domo Still Looks Cheap After Its Post-Earnings Rally

    Shares of Domo (NASDAQ: DOMO) recently rallied to all-time highs after the cloud analytics software provider's fourth-quarter numbers dazzled investors. Its revenue rose 31% annually to $39.4 million, beating estimates by $1.6 million. Domo's non-GAAP net loss narrowed from $39 million to $25 million, or $0.94 per share, which also topped expectations by $0.30.

  • A Look at AT&T's Valuation in March
    Business
    Market Realist

    A Look at AT&T's Valuation in March

    Key Updates from AT&T at the Deutsche Bank MIT Conference(Continued from Prior Part)AT&T's scale As of March 14, AT&T's (T) market capitalization was $220.6 billion, making it the second-largest US wireless service provider in terms

  • How Will Micron (MU) Stock React to Wednesday's Earning Release?
    Business
    SmarterAnalyst

    How Will Micron (MU) Stock React to Wednesday's Earning Release?

    With Micron's (MU) second-quarter results slated for announcement Wednesday after close, investors are eager to see how depressed average selling prices (ASPs) are impacting the semiconductor giant. Lower demand with high supply has pushed prices downwards, which has pushed revenue and expectations down, with its stock price following. While some analysts expect a price turnaround soon, Susquehanna analyst Mehdi Hosseini says this will not be enough.

  • Is Cloudera a Buy?
    Business
    Motley Fool

    Is Cloudera a Buy?

    In addition, the company's guidance for $835 million to $855 million of revenue in fiscal 2020 fell far short of the $965 million that Cloudera projected in its S-4 merger document last fall. While the headlines look bad, there's an awful lot of noise going on beneath these numbers, mostly involving accounting issues surrounding the integration of Hortonworks, which officially merged with Cloudera on Jan. 3. Sales disruption expected over the next two quarters and an accounting change are throwing off this year's numbers quite a bit.

  • Why Micron Stock Fell ahead of Its Q2 2019 Earnings Results
    Business
    Market Realist

    Why Micron Stock Fell ahead of Its Q2 2019 Earnings Results

    What's Different? (Continued from Prior Part)Micron stock falls ahead of its earnings Micron Technology's (MU) fiscal 2019 second-quarter earnings will likely feel the heat of the demand weakness in

  • Fiat Chrysler revs up as Peugeot points to merger potential
    Business
    Reuters

    Fiat Chrysler revs up as Peugeot points to merger potential

    Fiat Chrysler shares jumped on Tuesday to the top of Europe's STOXX 600 after the president of Peugeot family holding company FFP told French daily Les Echos he would support a new deal and suggested Fiat Chrysler was among the options. "With them, as with others, the planets could be aligned," Robert Peugeot was reported as saying, asked about targets for acquisitions or mergers. Fiat Chrysler (FCA) declined to comment.